About: Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 28 January 2019

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в січні 2019 (uk) artículu científicu espublizáu en xineru de 2019 (ast) im Januar 2019 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 28 January 2019 (en)
publication date	wds:Q64229599-32C6ADDC-AD4F-4B3E-B887-35A4147505E9
publication date	2019-01-28 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q64229599-0CB9658F-2840-414E-B400-484FC7739A17
language of work or name	English
cites work	wds:Q64229599-0400476F-A646-42D2-9315-993FB0A052CF wds:Q64229599-0C9C0F81-07D5-4032-97F1-568D52107031 wds:Q64229599-0EBB7B26-5DC9-4565-BB91-6846EC7EC65F wds:Q64229599-0FF970B1-F6D8-4F0B-984F-16127EB9710A wds:Q64229599-22FEC424-757F-44E8-8DDA-57ADD38DEE6F wds:Q64229599-2FE642DA-C1E5-4432-8F23-470D66927F9C wds:Q64229599-30FA4635-3DA1-4919-97B5-97A980477F1D wds:Q64229599-332AEC0C-5458-45C0-9255-A02BA2060AA9 wds:Q64229599-46E7F61D-7B0E-4E0C-83B3-480F187B4F08 wds:Q64229599-4B09A064-3B05-415C-94A3-CF3AB0AEFE5C wds:Q64229599-53F20D1E-9697-4C13-B551-459CA31BEB90 wds:Q64229599-626D115A-950F-4533-803F-9BAD4C5F7CA3 wds:Q64229599-6699E85B-D4A1-4AB6-8FFD-52F2CC143BA4 wds:Q64229599-6E87B217-76CE-42F4-90A2-DDD865288515 wds:Q64229599-770B1C54-EFDC-4803-AFC7-750D646B5FD3 wds:Q64229599-7A8C33C6-933E-4AC9-8F81-013C1217CACB wds:Q64229599-7EDE804B-BCE3-45B1-8A63-B9AC9FBB3708 wds:Q64229599-894DAC6A-35EE-4BD4-9D59-9B18C41CB692 wds:Q64229599-A4BB3934-3604-4C79-BA9D-E687C6522ADA wds:Q64229599-B6055586-2D6F-4495-87F9-2528F09FB4F3 wds:Q64229599-B7E902FE-AF91-428E-A042-D7F9375E56B7 wds:Q64229599-B9364A6B-FACF-4B8F-95EE-4C7AF6C77C61 wds:Q64229599-C278DFEE-7305-40EB-8012-57EE11C0C2E7 wds:Q64229599-C6CD2C37-355A-4071-9B82-E5E615CBD779 wds:Q64229599-C96DACAF-80AB-48AF-B187-DFB986B02552 wds:Q64229599-C99EFC5A-97A1-4A03-90F0-FE59B47C3545 wds:Q64229599-CC2B5115-04FF-42C6-94EE-F392F4710BD2 wds:Q64229599-CD11CB1B-1DB3-4F07-8181-E848EBAC6AE5 wds:Q64229599-CE345078-BD96-4794-8E61-D537BEE77697
cites work	The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis Bortezomib or high-dose dexamethasone for relapsed multiple myeloma Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study Update on the proteasome inhibitor bortezomib in hematologic malignancies Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation Biologicals for the treatment of systemic lupus erythematosus: current status and emerging therapies Therapy-related peripheral neuropathy in multiple myeloma patients. Myasthenia gravis and the neuromuscular junction The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients New insights into the immunopathogenesis of systemic lupus erythematosus. Patterns of acetylcholine receptor antibody fluctuation in myasthenia gravis The role of autoantibodies in the pathophysiology of rheumatoid arthritis Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 3. The effect of thymectomy. Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review Humoral immunity in myasthenia gravis: effect of steroids and thymectomy Rituximab treatment of myasthenia gravis: A systematic review Multicenter Double-Blind Randomized Controlled Trial to Evaluate the Effectiveness and Safety of Bortezomib as a Treatment for Refractory Systemic Lupus Erythematosus.
author name string	wds:Q64229599-4B9590B1-AE6C-4B3F-B6D6-7178DAF8FE07 wds:Q64229599-5C223910-6191-4AB8-A668-9925E77500AB wds:Q64229599-9FD26E73-D9D7-4EAE-A325-6509CC9A846B
author name string	Falk Hiepe Tobias Alexander Siegfried Kohler
rdfs:label	Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial (en) Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial (nl)
skos:prefLabel	Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial (en) Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial (nl)
name	Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial (en) Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial (nl)
author	wds:Q64229599-246F7082-6678-4E2C-8204-EF4998009282 wds:Q64229599-7E50B07D-B586-4B92-A5F3-6FB5BDA487D7 wds:Q64229599-D9F645B7-D053-4284-8940-46B7A5488B20
author	Ulrike Grittner Andreas Meisel Stefanie Märschenz
title	wds:Q64229599-A85535B6-08CA-46EA-A6AD-AF0149BE7962
title	Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial (en)
page(s)	wds:Q64229599-018283EE-9AE8-4C58-8F20-63376A616AEC
page(s)	e024523
instance of	wds:Q64229599-A12EC1A4-A38D-4F1F-A726-F861EB72FDA2
instance of	scholarly article
main subject	wds:Q64229599-2DA0761F-148D-4219-8C38-C002AD4AC8C3 wds:Q64229599-38DDBA09-A245-48B2-BAE5-A76FD5BF84EE wds:Q64229599-47694F84-EC6C-4CA6-8A8F-FFCE2DB4C3C0 wds:Q64229599-8713893C-96F4-446C-B6C9-ACC59BDC4B7A
main subject	rheumatology placebo immunology study protocol

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software